Eli Lilly and Company (NYSE:LLY) Stock Price Up 0.4% – Should You Buy?

Eli Lilly and Company (NYSE:LLY) was up 0.4% during mid-day trading on Friday . The company traded as high as $762.01 and last traded at $754.23. Approximately 1,023,972 shares traded hands during mid-day trading, a decline of 71% from the average daily volume of 3,496,101 shares. The stock had previously closed at $751.45.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on LLY shares. Cantor Fitzgerald assumed coverage on shares of Eli Lilly and Company in a report on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 target price on the stock. Guggenheim reiterated a “buy” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Berenberg Bank set a $970.00 price objective on Eli Lilly and Company in a report on Thursday, January 16th. Morgan Stanley reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Finally, Hsbc Global Res cut Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research note on Monday, April 28th. One research analyst has rated the stock with a sell rating, two have given a hold rating and nineteen have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $1,002.80.

Eli Lilly and Company Trading Down 2.0 %

The business has a 50 day moving average of $810.98 and a two-hundred day moving average of $810.88. The firm has a market capitalization of $697.73 billion, a price-to-earnings ratio of 62.87, a P/E/G ratio of 1.40 and a beta of 0.48. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The firm had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same period in the previous year, the company earned $2.58 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 45.2% compared to the same quarter last year. Equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.81%. The ex-dividend date of this dividend is Friday, May 16th. Eli Lilly and Company’s dividend payout ratio is currently 48.82%.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.14% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of LLY. RMR Wealth Builders grew its position in Eli Lilly and Company by 2.3% in the 4th quarter. RMR Wealth Builders now owns 4,686 shares of the company’s stock worth $3,618,000 after purchasing an additional 107 shares in the last quarter. Czech National Bank lifted its position in shares of Eli Lilly and Company by 6.3% during the 4th quarter. Czech National Bank now owns 170,840 shares of the company’s stock worth $131,888,000 after buying an additional 10,143 shares in the last quarter. Aprio Wealth Management LLC boosted its stake in shares of Eli Lilly and Company by 10.8% in the 4th quarter. Aprio Wealth Management LLC now owns 2,627 shares of the company’s stock worth $2,028,000 after buying an additional 257 shares during the last quarter. Matrix Trust Co bought a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $164,000. Finally, City Center Advisors LLC increased its position in shares of Eli Lilly and Company by 5.4% during the fourth quarter. City Center Advisors LLC now owns 565 shares of the company’s stock valued at $436,000 after acquiring an additional 29 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.